Not available
Quote | John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest (NYSE:HTD)
Last: | $20.06 |
---|---|
Change Percent: | -0.7% |
Open: | $20.03 |
Close: | $20.06 |
High: | $20.1 |
Low: | $19.9001 |
Volume: | 73,614 |
Last Trade Date Time: | 06/25/2024 03:00:00 am |
News | John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest (NYSE:HTD)
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84 th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enro...
2024-06-22 06:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest (NYSE:HTD)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest John Hancock Tax Advantaged Dividend (HTD) Headlines 3 Stocks Going Ex-Dividen | Stock_Tracker | investorshangout | 03/14/2014 7:53:19 PM |
chartguy89: HTD Stock Charts Last: +0.07 $HTD 1 Month Chart | chartguy89 | investorshangout | 03/05/2014 3:08:10 AM |
News, Short Squeeze, Breakout and More Instantly...
John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest Company Name:
HTD Stock Symbol:
NYSE Market:
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84 th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enro...
2024-06-22 06:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the...